We could not find any results for:
Make sure your spelling is correct or try broadening your search.
MONTREAL, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and...
MONTREAL, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and...
MONTREAL, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and...
No dose-limiting toxicities reported in two different weekly doses in heavily pre-treated patients Preliminary evidence of dose response includes significant tumor shrinkage and one patient with...
Addition of investigational RNA-targeted medicines build upon Theratechnologies’ foundational HIV portfolio Submissions to Health Canada planned for 2025 MONTREAL, Dec. 04, 2024 (GLOBE...
MONTREAL, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and...
New financing replaces existing credit facility to optimize Company’s capital structureFavorable interest rates and amortization schedules to free up approximately $19 million in cash in 2025 to...
Resubmission addresses questions raised in January 2024 Complete Response Letter F8 formulation intended to replace EGRIFTA SV® with simplified dosing for the treatment of excess abdominal fat in...
MONTREAL, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on development and...
MONTREAL, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on development and...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.19 | 8.05084745763 | 2.36 | 2.64 | 2.35 | 25969 | 2.51319078 | CS |
4 | -0.1 | -3.77358490566 | 2.65 | 3.13 | 2.35 | 51753 | 2.69758522 | CS |
12 | 0.83 | 48.2558139535 | 1.72 | 3.13 | 1.6 | 63666 | 2.13594366 | CS |
26 | 0.38 | 17.5115207373 | 2.17 | 3.13 | 1.59 | 41054 | 2.03089865 | CS |
52 | -0.08 | -3.04182509506 | 2.63 | 3.13 | 1.59 | 33045 | 2.01686641 | CS |
156 | -12.01 | -82.4862637363 | 14.56 | 16.56 | 1.22 | 36769 | 4.18768298 | CS |
260 | -11.65 | -82.0422535211 | 14.2 | 22.4 | 1.22 | 65263 | 10.47768761 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions